CN114222585A - 抗TCRδ可变1抗体的治疗用途 - Google Patents

抗TCRδ可变1抗体的治疗用途 Download PDF

Info

Publication number
CN114222585A
CN114222585A CN202080057206.1A CN202080057206A CN114222585A CN 114222585 A CN114222585 A CN 114222585A CN 202080057206 A CN202080057206 A CN 202080057206A CN 114222585 A CN114222585 A CN 114222585A
Authority
CN
China
Prior art keywords
antibody
seq
sequence
fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080057206.1A
Other languages
English (en)
Chinese (zh)
Inventor
N·芒特
O·波利亚科娃
R·古德
M·尤登
R·J·梅塔
O·努斯鲍默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gamma Delta Therapy Co ltd
Original Assignee
Gamma Delta Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1911799.3A external-priority patent/GB201911799D0/en
Priority claimed from GBGB2010760.3A external-priority patent/GB202010760D0/en
Application filed by Gamma Delta Therapy Co ltd filed Critical Gamma Delta Therapy Co ltd
Publication of CN114222585A publication Critical patent/CN114222585A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080057206.1A 2019-08-16 2020-08-14 抗TCRδ可变1抗体的治疗用途 Pending CN114222585A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1911799.3 2019-08-16
GBGB1911799.3A GB201911799D0 (en) 2019-08-16 2019-08-16 Novel Antibodies
GBGB2010760.3A GB202010760D0 (en) 2020-07-13 2020-07-13 Novel antibodies
GB2010760.3 2020-07-13
PCT/GB2020/051959 WO2021032963A1 (en) 2019-08-16 2020-08-14 Therapeutic uses of anti-tcr delta variable 1 antibodies

Publications (1)

Publication Number Publication Date
CN114222585A true CN114222585A (zh) 2022-03-22

Family

ID=72148174

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080057206.1A Pending CN114222585A (zh) 2019-08-16 2020-08-14 抗TCRδ可变1抗体的治疗用途
CN202080065477.1A Pending CN114514245A (zh) 2019-08-16 2020-08-14 新颖的抗TCRδ可变1抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080065477.1A Pending CN114514245A (zh) 2019-08-16 2020-08-14 新颖的抗TCRδ可变1抗体

Country Status (13)

Country Link
US (1) US20220403025A1 (cg-RX-API-DMAC7.html)
EP (2) EP4013505A1 (cg-RX-API-DMAC7.html)
JP (4) JP2022545196A (cg-RX-API-DMAC7.html)
KR (2) KR20220084019A (cg-RX-API-DMAC7.html)
CN (2) CN114222585A (cg-RX-API-DMAC7.html)
AU (4) AU2020332878B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022002837A2 (cg-RX-API-DMAC7.html)
CA (2) CA3145517A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022000368A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022002001A2 (cg-RX-API-DMAC7.html)
IL (1) IL290537A (cg-RX-API-DMAC7.html)
MX (1) MX2022002075A (cg-RX-API-DMAC7.html)
WO (2) WO2021032960A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
MX386714B (es) 2015-01-27 2025-03-11 Lava Therapeutics N V Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
WO2019147735A1 (en) 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
JP7457007B2 (ja) 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用CD1d免疫グロブリン
CA3127103A1 (en) 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
JP2022545196A (ja) * 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗tcrデルタ可変1抗体の治療的使用
GB202002581D0 (en) * 2020-02-24 2020-04-08 Gammadelta Therapeutics Ltd Novel antibodies
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
ES2943063T5 (en) * 2020-08-14 2026-05-05 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies
MX2023009544A (es) 2021-02-17 2023-11-28 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecíficos.
KR20230160253A (ko) 2021-02-17 2023-11-23 감마델타 테라퓨틱스 엘티디 항-tcr 델타 가변 1 항체
EP4147716A1 (en) * 2021-09-10 2023-03-15 Samatva Research Corporation Anti-virus moiety immobilised in a matrix
CA3208653A1 (en) 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
EP4688851A1 (en) 2023-03-27 2026-02-11 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
CN121752599A (zh) * 2023-08-31 2026-03-27 南京传奇生物科技有限公司 抗γδTCR抗体及其用途
WO2026087747A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof
WO2026087748A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof
US20260152558A1 (en) 2024-11-27 2026-06-04 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031641A (zh) * 2004-08-19 2007-09-05 伯哈德·莫瑟 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途
CN109414480A (zh) * 2016-04-15 2019-03-01 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
WO2019147735A1 (en) * 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
CN102295702B (zh) * 2011-08-26 2014-01-29 中国科学院微生物研究所 一种针对t细胞受体可变区特异性单抗的制备方法
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
RU2756247C2 (ru) * 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
JP6799895B2 (ja) 2015-06-09 2020-12-16 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. TCRγδ+T細胞の生産方法
CN108473958A (zh) 2015-10-30 2018-08-31 癌症研究技术有限公司 非造血组织驻留γδT细胞的扩增及这些细胞的用途
CN118421557A (zh) 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
JP7686571B2 (ja) * 2019-05-08 2025-06-02 ヤンセン バイオテツク,インコーポレーテツド T細胞媒介性免疫を調節するための材料及び方法
JP2022545196A (ja) * 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗tcrデルタ可変1抗体の治療的使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031641A (zh) * 2004-08-19 2007-09-05 伯哈德·莫瑟 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途
CN109414480A (zh) * 2016-04-15 2019-03-01 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
WO2019147735A1 (en) * 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor

Also Published As

Publication number Publication date
BR112022002837A2 (pt) 2022-05-10
CL2024002250A1 (es) 2024-11-29
MX2022002075A (es) 2022-03-17
WO2021032963A1 (en) 2021-02-25
CN114514245A (zh) 2022-05-17
EP4013505A1 (en) 2022-06-22
AU2020332878B2 (en) 2026-07-30
AU2026205504A1 (en) 2026-07-30
IL290537A (en) 2022-04-01
WO2021032960A1 (en) 2021-02-25
AU2020332878A1 (en) 2022-01-27
AU2020333406B2 (en) 2026-07-30
KR20220084019A (ko) 2022-06-21
AU2026205443A1 (en) 2026-08-06
KR20220084020A (ko) 2022-06-21
CO2022002001A2 (es) 2022-04-08
EP4013504A1 (en) 2022-06-22
AU2020333406A1 (en) 2022-01-27
US20220403025A1 (en) 2022-12-22
JP2026009903A (ja) 2026-01-21
CA3145517A1 (en) 2021-02-25
CA3145523A1 (en) 2021-02-25
JP2022545196A (ja) 2022-10-26
JP2022544683A (ja) 2022-10-20
CL2022000368A1 (es) 2022-09-30
JP2025160218A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
US20230028110A1 (en) Anti-tcr delta variable 1 antibodies
JP7847579B2 (ja) 多特異性抗tcrデルタ可変1抗体
US20220403025A1 (en) Therapeutic uses of anti-tcr delta variable 1 antibodies
CN117999282A (zh) 抗TCRδ可变1抗体
HK40104904A (en) Anti-tcr delta variable 1 antibodies
HK40092859A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40103477A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40097714A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40103226A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40102396A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40103002B (en) Multispecific anti-tcr delta variable 1 antibodies
HK40103002A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40102395B (en) Multispecific anti-tcr delta variable 1 antibodies
HK40102395A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40076296B (en) Multispecific anti-tcr delta variable 1 antibodies
HK40076296A (en) Multispecific anti-tcr delta variable 1 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination